Medical Oncology
No mentions found
This entity hasn't been tracked yet, or Iris is still building its knowledge base.
Related Articles from SNS
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
GSK to buy US cancer treatment firm Nuvalent for $10.6bn
British drugmaker’s new chief executive Luke Miels announces one of its biggest dealsBusiness live – latest updatesGSK’s new boss Luke Miels has struck one of the British drugmaker’s biggest deals, announcing the $10.6bn (£7.9bn) acquisition of a US cancer specialist with two-late stage medications. The FTSE 100 company is boosting its oncology portfolio by agreeing to buy Nuvalent, a Boston-based biotech that develops cancer drugs, including three for lung cancer. GSK will pay $124 a share...
Automated Report-Derived Oncology VQA Benchmark for Evaluating Vision-Language Models on 3D Medical Imaging
arXiv:2606.02809v1 Announce Type: new Abstract: Evaluating vision-language models (VLMs) on medical images requires benchmarks that are clinically grounded, scalable, and controlled for evaluation confounds. Existing public benchmarks are limited in scale, manually annotated, or potentially leaked into VLM pretraining corpora. We present an automated agent-driven pipeline that generates multiple-choice VQA datasets directly from paired private radiology reports and 3D oncology imaging,...
Fear of recurrence: How immune memory helps cancer survivors face their worst nightmare
Every year the world observes National Cancer Survivors Month in June, celebrating the growing number of people who have successfully completed cancer treatment and are building lives beyond their diagnosis. For many survivors, however, the end of treatment does not always bring complete peace of mind. Even years later, routine scans, follow-up appointments or unexplained aches can revive a lingering question: What if the cancer comes back?
A personalized vaccine for melanoma cut the risk of cancer returning after five years
An experimental vaccine from Moderna shows promise in keeping deadly skin cancer from returning for years, according to new clinical trial results. The research, presented Monday at the American Society of Clinical Oncology’s annual meeting, found that a personalized mRNA vaccine halved the risk of melanoma returning after five years. The results were also published in the Journal of Clinical Oncology.
A hotly debated lung cancer drug cut the risk of death by 34% in a late-stage trial in China
An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a closely watched late-stage trial, according to results released Sunday. When combined with chemotherapy, the drug kept people with squamous non-small-cell lung cancer alive for a median of four months longer than the standard combination of immunotherapy and chemotherapy, a result that was statistically significant, according to an abstract released Sunday ahead of a presentation at the...
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival
Scientists finally crack an “undruggable” pancreatic cancer target and nearly double survival A once-“undruggable” pancreatic cancer target has finally been cracked, and the new treatment nearly doubled survival in a landmark trial. - Date: - June 4, 2026 - Source: - The Conversation - Summary: -
Chemotherapy drug supply crisis hits cancer care
NEW DELHI: Cancer patients across India are scrambling to procure two life-saving chemotherapy drugs as a shortage of Cisplatin and Carboplatin begins to disrupt treatment schedules. Doctors at AIIMS Delhi, private hospitals and cancer centres across the country warn that prolonged shortages could affect outcomes for patients undergoing curative treatment. Hospitals are reporting dwindling stocks, while patients and their families are being forced to hunt for pharmacies and distributors...
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk
Ozempic and similar weight-loss drugs linked to 30% lower breast cancer risk Popular GLP-1 weight-loss drugs may have an unexpected bonus: a significantly lower risk of breast cancer. - Date: - June 6, 2026 - Source: - University of Pennsylvania School of Medicine - Summary: - A large study found that women taking GLP-1 drugs, the medication class behind Ozempic, Wegovy, Mounjaro, and Zepbound, were about 30% less likely to develop breast cancer.